What Increlex 10mg/ml Treats: Main Uses and Benefits

Increlex (Mecasermin) is a specialized medication generally used for pediatric patients aged two years and older to manage their condition. It is applied across therapeutic domains where additional symptomatic support is needed to address severe growth failure stemming from specific hormonal deficiencies and related growth disorders.

It is relevant in situations involving systemic imbalance, such as specific forms of severe, primary growth factor deficiency and related growth disorders. The medication contributes to easing the overall symptom load by supplying a critical factor necessary for growth. Increlex is relevant for managing patients with symptoms that create noticeable physiological strain, like extremely short stature and profoundly low IGF-1 levels. The treatment may assist with supporting the patient’s physical growth, and assists with maintaining functional stability in the development of bone and muscle structure.

---

Quick Fact: Relief for Growth Failure
This medication provides supportive relief when symptoms interfere with routine activities related to growth.

Increlex (mecasermin) is a prescription medicine containing recombinant human Insulin-like Growth Factor-1 (IGF-1), and its use is strictly defined. It is indicated for the long-term treatment of growth failure in children, typically those 2 years of age and older, who have been diagnosed with a severe form of primary IGF-1 deficiency.

Primary IGF-1 deficiency is a rare condition defined by a combination of a low height standard deviation score, low basal IGF-1 levels, and normal or elevated Growth Hormone (GH) levels, indicating the body does not properly respond to GH. It is also approved for growth failure in patients with a GH gene deletion who have developed neutralizing antibodies to GH.

---

Who Should Not Use Increlex?

The medication is contraindicated (should not be used) in patients with the following conditions:

Condition	Reason for Contraindication
Closed Epiphyses (finished growing)	The drug promotes growth, which is not possible after the growth plates have fused.
Active or Suspected Malignant Neoplasia (cancer)	IGF-1 can stimulate cell growth, which may promote tumor growth.
Known Hypersensitivity	Severe allergy to mecasermin or any inactive ingredients (e.g., benzyl alcohol) in the injection.

It is not indicated for growth failure due to secondary causes, such as Growth Hormone (GH) deficiency, malnutrition, or chronic steroid use, as these conditions should be treated by addressing the underlying cause.

The interaction profile for Increlex (Mecasermin) is formally documented around its inherent insulin-like activity, which establishes core pharmacodynamic interaction patterns. Co-administration with insulin or other hypoglycaemic medicinal products may result in additive hypoglycaemic effects, increasing the risk and severity of low blood sugar. Regulatory documentation notes that the dose of the co-administered agent may require adjustment due to this documented synergism.

Administration Timing and Restrictions

To mitigate the risk of hypoglycemia, a mandatory timing rule applies: the medicine must be administered shortly before or shortly after (pm 20 minutes) a meal or snack. The product must not be administered if a meal is omitted. Certain herbal products with documented glucose-lowering effects may similarly potentiate this risk.

Official regulatory documents also list specific prohibitions. Intravenous administration is a prohibited route. The medicine is contraindicated for use in patients with active or suspected neoplasia.

Population and Excipient Restriction

A composition-population restriction is documented because the excipient benzyl alcohol is present in the formulation, which formally contraindicates the product’s use in neonates or premature babies.

The mechanism of action for Mecasermin is centered on initiating biological signals required for growth and tissue anabolism.

Direct IGF-1R Agonism and Signal Transduction

Mecasermin is a direct agonist for the Type I Insulin-like Growth Factor Receptor ( IGF-1R), the key molecular target that mediates the primary growth signal. By binding to and activating this receptor, Mecasermin initiates the cell's intrinsic tyrosine kinase activity, which is the first step in a major intracellular cascade responsible for driving cellular function and proliferation.

Anabolic and Mitogenic Pathway Activation

The receptor activation event feeds into two primary signaling pathways: the PI3K/AKT/mTOR cascade, which promotes anabolism and protein synthesis, and the Ras-MAPK pathway, which drives mitogenesis and cellular differentiation. This dual activation is crucial for both increasing protein synthesis in muscle and stimulating the proliferation of chondrocytes (cartilage cells) in the bone growth plates.

Systemic Elongation and Physiological Constraint

The ultimate physiological consequence of these activated pathways is the resulting linear skeletal elongation and systemic anabolism. However, this mechanism is physiologically constrained; its effectiveness for skeletal elongation is entirely dependent on the presence of open epiphyseal growth plates, meaning the growth signal cannot proceed once skeletal maturity is reached.

Administration Process

Increlex is administered via subcutaneous injection, typically into the fatty tissue just beneath the skin. Common injection sites include the upper arms, thighs, buttocks, or abdomen. It is important to rotate the injection site for each administration to help prevent the development of localized skin reactions or lipohypertrophy.

Timing and Diet

The administration of this medication is closely linked to nutritional intake. It should be injected shortly before or shortly after a meal or snack. This timing is essential because the active ingredient mimics natural insulin-like growth factors which can influence blood sugar levels. If a meal is missed or cannot be consumed, the administration should be deferred to avoid potential metabolic imbalances.

Preparation and Handling

The solution should be inspected visually prior to use; it should be clear and colorless. If the liquid is cloudy, contains particulate matter, or shows any discoloration, the vial should not be used. The medication must be handled with care, following standard aseptic techniques to ensure the integrity of the solution and the injection site.

Storage Considerations

To maintain the stability of the protein, the medication requires specific temperature controls. Vials should be kept in a refrigerated environment and protected from direct light. Once a vial has been opened, it can typically be used for a limited period, provided it is stored correctly and handled according to clinical standards. It should never be frozen or shaken vigorously, as this can denature the active components.

Research Evidence / Overview of Studies for Increlex 10mg/ml

The research base for Increlex (mecasermin) focuses on its clinical evaluation for specific, very rare growth disorders. The research structure reflects the rarity of the condition, meaning the limited number of eligible patients restricts the size and design of the available trials. The medicine was evaluated in research exploring outcomes related to severe growth disorders where IGF-1 deficiency is a factor.

---

Evidence for Use in Severe Primary IGF-1 Deficiency (SPIGFD)

Research examining use in Severe Primary IGF-1 Deficiency (SPIGFD) primarily utilized small, open-label trials. The main focus of these trials centered on measuring the annual speed of linear growth, known as Height Velocity, and monitoring changes in Height Standard Deviation Score (SDS). Studies reported findings of Height Velocity measurements in the populations studied. However, the evidence is considered limited as the core research did not include a robust, parallel control group receiving a placebo, meaning comparative evidence is limited for the primary outcomes studied.

---

Research Structure, Long-Term Follow-Up, and Uncertainties

The research base also evaluated outcomes in specific genetic conditions, including Laron Syndrome. The necessary follow-up for a medicine studied in growth disorders required observation over defined time intervals. Large, observational patient registries were established, with some patient observation data extending up to 12 years. The long-term research has explored the attainment of Near-Adult Height (NAH).

The evidence base is specifically focused on the pediatric population (age two years and older) with open growth plates. There are insufficient data available to draw conclusions about its use in other age groups, such as older adults, or in populations with comorbid conditions.

What remains uncertain is the long-term status of systemic outcomes beyond growth. Limited data was observed regarding the effects on secondary endpoints such as bone density, heart function, or lung capacity. The evidence quality varies across studies based on design and patient numbers.

Key Studies & References Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD) - ClinicalTrials.gov (NCT00903110)

Common questions about Increlex 10mg/ml (FAQ)

Q: What are the common signs of hypoglycemia that a patient/parent should be aware of?

According to the official product information, low blood sugar (hypoglycemia) is a very common side effect. Signs that a person's blood sugar may be too low can include dizziness, tiredness, sweating, hunger, nausea, irritability, restlessness, trouble concentrating, or having a fast or irregular heartbeat.

Q: Is it normal to feel dizzy or tired in the hours after an injection?

Feeling dizzy or tired after an injection is listed in the official patient information as a common sign of low blood sugar (hypoglycemia). Since low blood sugar is the most common side effect and often occurs after the injection, awareness of these symptoms is part of understanding the drug’s safety profile.

Q: What are the symptoms of enlarged lymphoid tissue or tonsil hypertrophy?

Official information indicates that tonsillar/adenoidal hypertrophy (enlarged lymph tissue) is a reported side effect. Symptoms that may be associated with this issue include snoring, difficulty breathing, fluid in the middle-ear, or brief stopping of breathing during sleep, which is known as sleep apnea.

Q: Why would a doctor recommend a periodic eye exam while on Increlex?

The product label recommends a specific eye examination, known as a funduscopic examination, before starting therapy and periodically thereafter. This procedure is described as a way to monitor for signs of Increased Intracranial Pressure (IICP), which is a rare but serious side effect reported in official documents.

Q: Can Increlex affect the use of steroid medications for other conditions?

The medicine is officially not indicated for growth failure caused by chronic treatment with high doses of anti-inflammatory steroids. The labeling indicates that growth failure caused by chronic steroid treatment is a condition that must be addressed, as it is a factor that impacts the decision to use the medicine.

Q: Is it safe to use Increlex if a person has kidney or liver problems?

While the core regulatory label does not list these as contraindications, liver or kidney impairment is a key clinical consideration noted in official documentation. These conditions are a factor in determining eligibility for the medicine.

Q: Can Increlex cause changes in fat tissue (lipoatrophy or lipohypertrophy) at the injection site?

Yes, regulatory documentation states that reactions at the injection site can occur. These reactions may involve the tissue beneath the skin, including a loss of fat (lipoatrophy) or an increase of fat (lipohypertrophy) where the injection is administered.

Q: Why is there a specific warning about engaging in 'high-risk activities' after the injection?

Official warnings exist because the drug is associated with a risk of severe hypoglycemia (low blood sugar). To mitigate this risk, patients are advised to avoid participating in high-risk activities like driving or rigorous exercise in the 2 to 3 hours following the injection, especially early in treatment.

Q: Are allergic reactions to mecasermin or its ingredients common?

Official patient information describes allergic reactions as a serious but common side effect. Reported reactions can be localized to the injection site or be more widespread, systemic reactions.

Q: What is the risk of a severe allergic reaction, such as anaphylaxis?

The official warnings note that a low number of cases indicative of anaphylaxis (a severe allergic reaction) have been reported in post-marketing experience. The labeling includes this information as part of educating patients and caregivers on the drug’s risk profile.

Q: Does the body develop antibodies to Increlex over time?

Regulatory information indicates that the body may develop an antibody response to the injected medicine in some patients. If a patient does not respond as expected in growth or has unexpected changes in blood IGF-1 levels, this antibody response is one potential explanation that may be investigated.

Q: If a child has a temporary illness, should Increlex still be given?

Official warnings state that the medicine must be withheld if the patient is unable to eat a meal or snack shortly before or after the injection for any reason. If a temporary illness interferes with the ability to eat, the dose should not be given.

Q: Does Increlex affect sleep patterns, such as causing or worsening sleep apnea?

Yes, sleep apnea has been reported as an adverse reaction in official safety documents. This reaction is often associated with the growth of lymphoid tissue, such as enlarged tonsils, which can affect a patient's breathing during sleep.

Storage and Disposal Requirements

Official regulatory documents define strict storage and handling rules for Increlex (mecasermin) to maintain its integrity.

Mandatory Storage Conditions

• Temperature: Store the solution in a refrigerator at 2 C to 8 C.
• Freezing: The product must not be frozen.
• Light Protection: Keep the unopened vial in the original outer carton to protect it from light.

Stability and Handling

• In-Use Period: Once the vial is opened (first use), the multi-dose solution must be discarded after 30 days, even if kept continuously refrigerated.
• Inspection: Always inspect the solution prior to use; do not use it if it appears cloudy or contains particulate matter.

Disposal

• Any unused product or waste material must be disposed of strictly in accordance with local regulations and requirements.